Innovent Biologics’ Taletrectinib Receives Second NDA Acceptance in China for ROS1 Positive NSCLC
Innovent Biologics Inc., (HKG: 1801), a biopharmaceutical company based in China, has announced that the...
BMS Reports Positive Long-Term Data for Zeposia in Multiple Sclerosis Trials
Bristol Myers Squibb (BMS; NYSE: BMY) has unveiled results from several Phase III trials for...
BeiGene’s Brukinsa Outperforms Acalabrutinib in MAIC for Relapsed/Refractory CLL, Says BeiGene
BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced the results of a matching-adjusted...
Merck’s Mavenclad Demonstrates Lasting Efficacy in RMS Patients, New Data Show
Merck KGaA (ETR: MRK), a German multinational pharmaceutical, chemical, and life sciences company, has this...
AlzeCure Pharma’s Alzheimer’s Drug Candidate ACD856 Receives Global Patent Awards
AlzeCure Pharma, a Swedish pharmaceutical company, has announced the receipt of patent approval awards for...
Sino-Biocan Secures Series B Funding to Boost Cell and Gene Therapy Production Platforms
Sino-Biocan (Shanghai) Biotech Ltd, a provider of automated, modularized, closed cell production platforms for the...
AIM Vaccine Advances Pneumococcal Vaccine and Initiates Phase II Meningococcal Study
AIM Vaccine Co., Ltd (HKG: 6660) has delivered a series of updates on the development...
ArkBio Partners with SDODT to Boost ADHD Treatment Marketing and Commercialization
Shanghai Ark Biopharmaceutical Co., Ltd (ArkBio), a Chinese biopharmaceutical company, has entered into a partnership...
Hainan Poly Pharm Secures Tentative FDA Approval for Generic Version of UCB’s Briviact
Hainan Poly Pharm Co., Ltd (SHE: 300630), a Chinese pharmaceutical company, has announced that it...
BMS’s Yervoy-Opdivo Combo on Track for Breakthrough Therapy Designation in China for CRC
The China Center for Drug Evaluation (CDE) website has indicated that the market approval filing...
Beijing Tinavi Medical Technologies to Form Radiotherapy Equipment JV with IM INNO and Celestial Oncology
Beijing Tinavi Medical Technologies Co., Ltd (SHA: 688277) has announced its intention to establish a...
Pfizer’s RSV Vaccine Demonstrates Durable Efficacy with Abrysvo Phase III Results
Pfizer Inc. (NYSE: PFE) last week reported the outcomes of a Phase III trial for...
Biden’s Executive Order May Restrict Data Access for China-Based Life Science Firms in the US
US President Joe Biden last week issued an Executive Order titled “Preventing Access to Americans’...
Shanghai Fosun Pharma’s GCK-01 CAR-NK Cell Therapy Gets Tacit Clinical Approval from China’s CDE
The China Center for Drug Evaluation (CDE) website has indicated that Shanghai Fosun Pharmaceutical (Group)...
J&J’s Rybrevant Secures Full FDA Approval for NSCLC with EGFR Exon 20 Insertions
The US Food and Drug Administration (FDA) has granted Johnson & Johnson (J&J; NYSE: JNJ)...
Astellas Launches Late-Stage Trial in Japan for Nonhormonal Menopause Treatment
Astellas Pharma Inc. (TYO: 4503), a leading Japanese pharmaceutical company, last week initiated a late-stage...
Hebei Province Proposes Measures for ‘Internet+’ Medical Services and Insurance Management
The Hebei provincial Healthcare Security Administration (HSA) bureau has released a draft set of Measures...
Maruho Expands into China with New Wholly Owned Subsidiary in Beijing
Japan-based Maruho has announced the establishment of a wholly owned subsidiary in Beijing, marking its...
Sino-US Laekna’s LAE102 Clinical Trial Filing Accepted for Review in Obesity and Metabolic Disorders
Sino-US Laekna (HKG: 2105) has announced that its clinical trial application for LAE102, an antibody...
Haihe Pharmaceuticals Licenses Glumetinib to Taiho for Exclusive Development in Japan and Asia
Shanghai Haihe Pharmaceutical Co., Ltd has entered into a licensing agreement with Taiho Pharmaceutical Co.,...